Obesity pill race heats up

Core Insights - The trial data from Lily indicates that its obesity pill may serve as an effective maintenance treatment for individuals who wish to sustain their weight loss without the need for weekly injections like Wgoian Zepbound [2][3] - Participants who switched to the pill after initially using injections maintained most of their weight loss, with the WGOI group regaining only about 2 pounds and the Zeppbound group regaining around 11 pounds over a year [3] Pricing and Market Implications - The exact pricing for the obesity pill has not been disclosed, but initial estimates suggest a starting cost of $150 per month for cash-paying patients, significantly lower than the over $1,000 monthly cost for injectable versions [5][6] - The Trump administration's deal is expected to expand Medicare coverage for obesity drugs, marking a significant change anticipated in early to mid-2026 [7]